These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

758 related articles for article (PubMed ID: 25989278)

  • 1. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer.
    Rowland A; Dias MM; Wiese MD; Kichenadasse G; McKinnon RA; Karapetis CS; Sorich MJ
    Br J Cancer; 2015 Jun; 112(12):1888-94. PubMed ID: 25989278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours.
    Rowland A; Dias MM; Wiese MD; Kichenadasse G; McKinnon RA; Karapetis CS; Sorich MJ
    Eur J Cancer; 2016 Mar; 55():122-30. PubMed ID: 26812186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis.
    Chen D; Li L; Zhang X; Gao G; Shen L; Hu J; Yang M; Liu B; Qian X
    Medicine (Baltimore); 2018 Mar; 97(10):e0097. PubMed ID: 29517682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.
    Pietrantonio F; Petrelli F; Coinu A; Di Bartolomeo M; Borgonovo K; Maggi C; Cabiddu M; Iacovelli R; Bossi I; Lonati V; Ghilardi M; de Braud F; Barni S
    Eur J Cancer; 2015 Mar; 51(5):587-94. PubMed ID: 25673558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
    Lu X; Li Y; Li Y; Zhang X; Shi J; Feng H; Yu Z; Gao Y
    BMC Cancer; 2023 Nov; 23(1):1117. PubMed ID: 37974093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis.
    Yang ZY; Wu XY; Huang YF; Di MY; Zheng DY; Chen JZ; Ding H; Mao C; Tang JL
    Int J Cancer; 2013 Oct; 133(8):1914-25. PubMed ID: 23494461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive and prognostic roles of BRAF mutation in patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a meta-analysis.
    Xu Q; Xu AT; Zhu MM; Tong JL; Xu XT; Ran ZH
    J Dig Dis; 2013 Aug; 14(8):409-16. PubMed ID: 23615046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
    Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
    Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of primary tumor sidedness and sex on prognosis and anti-epidermal growth factor receptor antibody efficacy in BRAF-mutant metastatic colorectal cancer: a pooled analysis of AIO studies FIRE-1, CIOX, FIRE-3, XELAVIRI, and VOLFI.
    Alig AHS; Modest DP; Stintzing S; Heinrich K; Geissler M; Fischer von Weikersthal L; Decker T; Vehling-Kaiser U; Held S; Moosmann N; Stahler A; Tannapfel A; Giessen-Jung C; Jung A; Weiss L; Heinemann V
    ESMO Open; 2024 Sep; 9(9):103677. PubMed ID: 39173562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database.
    Karapetis CS; Liu H; Sorich MJ; Pederson LD; Van Cutsem E; Maughan T; Douillard JY; O'Callaghan CJ; Jonker D; Bokemeyer C; Sobrero A; Cremolini C; Chibaudel B; Zalcberg J; Adams R; Buyse M; Peeters M; Yoshino T; de Gramont A; Shi Q
    Br J Cancer; 2024 May; 130(8):1269-1278. PubMed ID: 38402342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Impact of PI3K/BRAF Mutations in RAS Wild Metastatic Colorectal Cancer: Meta-analysis Results.
    Mohamed A; Twardy B; AbdAllah N; Akhras A; Ismail H; Zordok M; Schrapp K; Attumi T; Tesfaye A; El-Rayes B
    J Gastrointest Cancer; 2019 Jun; 50(2):269-275. PubMed ID: 29388061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status.
    Siena S; Rivera F; Taieb J; Peeters M; Prenen H; Koukakis R; Demonty G; Köhne CH
    Clin Colorectal Cancer; 2018 Mar; 17(1):50-57.e8. PubMed ID: 29096990
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    van Brummelen EMJ; de Boer A; Beijnen JH; Schellens JHM
    Oncologist; 2017 Jul; 22(7):864-872. PubMed ID: 28576857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.
    Ålgars A; Sundström J; Lintunen M; Jokilehto T; Kytölä S; Kaare M; Vainionpää R; Orpana A; Österlund P; Ristimäki A; Carpen O; Ristamäki R
    Int J Cancer; 2017 Feb; 140(4):922-929. PubMed ID: 27879995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of anti-epidermal growth factor antibody rechallenge in RAS/BRAF wild-type metastatic colorectal cancer: a multi-institutional observational study.
    Fukuda K; Osumi H; Yoshinami Y; Ooki A; Takashima A; Wakatsuki T; Hirano H; Nakayama I; Ouchi K; Sawada R; Fukuoka S; Ogura M; Takahari D; Chin K; Shoji H; Okita N; Kato K; Ishizuka N; Boku N; Yamaguchi K; Shinozaki E
    J Cancer Res Clin Oncol; 2024 Jul; 150(7):369. PubMed ID: 39066951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial.
    Napolitano S; De Falco V; Martini G; Ciardiello D; Martinelli E; Della Corte CM; Esposito L; Famiglietti V; Di Liello A; Avallone A; Cardone C; De Stefano A; Montesarchio V; Zampino MG; Bordonaro R; Scartozzi M; Santini D; Di Maio M; De Vita F; Altucci L; Marrone F; Ciardiello F; Troiani T
    JAMA Oncol; 2023 Jul; 9(7):966-970. PubMed ID: 37200022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer: a meta-analysis.
    Song QB; Wang Q; Hu WG
    World J Gastroenterol; 2015 Apr; 21(14):4365-72. PubMed ID: 25892888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.
    Tol J; Dijkstra JR; Klomp M; Teerenstra S; Dommerholt M; Vink-Börger ME; van Cleef PH; van Krieken JH; Punt CJ; Nagtegaal ID
    Eur J Cancer; 2010 Jul; 46(11):1997-2009. PubMed ID: 20413299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic role of BRAF mutation in metastatic colorectal cancer receiving anti-EGFR monoclonal antibodies: a meta-analysis.
    Yuan ZX; Wang XY; Qin QY; Chen DF; Zhong QH; Wang L; Wang JP
    PLoS One; 2013; 8(6):e65995. PubMed ID: 23776587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
    Tol J; Punt CJ
    Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.